Syndax Pharmaceuticals Inc (STU:1T3)
€ 18.4 0.6 (3.37%) Market Cap: 1.59 Bil Enterprise Value: 1.18 Bil PE Ratio: 0 PB Ratio: 3.47 GF Score: 51/100

Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 02:45PM GMT
Release Date Price: €21
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

(technical difficulty)

the Barclays Healthcare Conference in Miami. Do e-mail us or messages on Bloomberg, if you have any questions. My name is Peter Lawson. I'm one of the SMID cap biotech analyst at Barclays. I'm really delighted to have up on stage with this pretty broad representation of management from Syndax. So we've got Michael Metzger, CEO and Director; Anjali Ganguli, Chief Business Officer; and Keith Goldan, CFO.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

So I guess first question is just around Menin inhibitor and the Phase II kind of how enrollment's going? And I'd love to know about this kind of the pace of enrollment -- so augment 101 kind of between the 2 different classes of the MPN1 versus rearranged or [KPM2]?

Michael A. Metzger
Syndax Pharmaceuticals, Inc. - CEO & Director

Maybe if you don't mind. First of all, thank you for having us. It's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot